Edgewise Therapeutics, Inc. Financials
This page shows Edgewise Therapeutics, Inc. (EWTX) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 6 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Edgewise is operating like an equity-funded drug developer, with rising research spend driving a larger operating cash burn.
From FY2023 to FY2025, operating cash burn widened from-$91.9M to-$143.8M while free cash flow stayed almost identical, showing the heavier spending is coming from people and programs rather than from building a capital-heavy asset base. Across the same span, financing inflows kept refilling the balance sheet, including$196.1M in FY2025, and shares outstanding reached 106.2M, so dilution has been the main funding mechanism instead of debt.
FY2025 spending was still overwhelmingly R&D-led:
The balance sheet is liquid but burn-dependent, with current assets of
Financial Health Signals
Edgewise Therapeutics, Inc. does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
Edgewise Therapeutics, Inc. passes 0 of 6 computable financial strength tests (3 of the nine could not be computed from available data). No profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).
Edgewise Therapeutics, Inc. reported a net loss of $168K while operations used $143.8M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
Edgewise Therapeutics, Inc.'s EBITDA was -$189.1M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 20.8% from the prior year.
Edgewise Therapeutics, Inc. reported -$168K in net income in fiscal year 2025. This represents a decrease of 25.4% from the prior year.
Edgewise Therapeutics, Inc. earned -$1.63 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 12.4% from the prior year.
Not reported for fiscal year 2025.
Cash & Balance Sheet
Edgewise Therapeutics, Inc. recorded an outflow of $144.1M in free cash flow in fiscal year 2025, representing a cash shortfall after capex. This represents a decrease of 30.6% from the prior year.
Edgewise Therapeutics, Inc. held $61.1M in cash as of fiscal year 2025; long-term debt is not reported for that period.
Not reported for fiscal year 2025.
Margins & Returns
Edgewise Therapeutics, Inc.'s ROE was 0.0% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. That is unchanged from the prior year.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Capital Allocation
Edgewise Therapeutics, Inc. invested $151.4M in research and development in fiscal year 2025. This represents an increase of 19.2% from the prior year.
Edgewise Therapeutics, Inc. invested $256K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 80.5% from the prior year.
Not reported for fiscal year 2025.
EWTX Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 |
|---|---|---|---|---|---|---|---|
| R&D Expenses | N/A | $151.4M+19.2% | $127.0M+39.7% | $90.9M+68.2% | $54.0M+67.9% | $32.2M+114.8% | $15.0M |
| SG&A Expenses | N/A | $40.0M+25.6% | $31.9M+35.9% | $23.5M+33.1% | $17.6M+59.9% | $11.0M+399.1% | $2.2M |
| Operating Income | N/A | -$191.4M-20.5% | -$158.8M-38.9% | -$114.4M-59.6% | -$71.7M-65.8% | -$43.2M-151.4% | -$17.2M |
| Income Tax | N/A | $4K+33.3% | $3K-25.0% | $4K | $0 | $0 | N/A |
| Net Income | N/A | -$168K-25.4% | -$134K-33.6% | -$100K+99.9% | -$67.6M-58.0% | -$42.8M-150.0% | -$17.1M |
| EPS (Diluted) | — | -$1.63-12.4% | -$1.45+7.6% | -$1.57 | -$1.26-10.5% | -$1.14 | -$23.17 |
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, Interest Expense.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
EWTX Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 |
|---|---|---|---|---|---|---|
| Total Assets | $552.6M+13.5% | $486.8M+43.2% | $340.0M-7.4% | $367.1M+28.7% | $285.2M+117.5% | $131.1M |
| Current Assets | $543.4M+14.3% | $475.5M+45.4% | $327.0M-8.4% | $357.0M+25.8% | $283.8M+118.9% | $129.6M |
| Cash & Equivalents | $61.1M+46.8% | $41.7M-51.6% | $86.1M+291.5% | $22.0M+41.3% | $15.6M-85.2% | $104.9M |
| Total Liabilities | $30.3M+9.9% | $27.6M+30.2% | $21.2M+4.0% | $20.4M+87.9% | $10.8M-93.4% | $164.6M |
| Current Liabilities | $27.4M+14.7% | $23.9M+42.3% | $16.8M+1.1% | $16.6M+57.6% | $10.5M+142.3% | $4.3M |
| Total Equity | $522.3M+13.7% | $459.2M+44.0% | $318.8M-8.0% | $346.7M+26.4% | $274.4M+921.0% | -$33.4M |
| Retained Earnings | -$546.4M-44.3% | -$378.6M-54.7% | -$244.8M-69.3% | -$144.6M-87.9% | -$77.0M-125.4% | -$34.1M |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.
EWTX Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 |
|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$158.4M | -$143.8M-31.9% | -$109.0M-18.6% | -$91.9M-74.7% | -$52.6M-57.1% | -$33.5M-129.0% | -$14.6M |
| Capital Expenditures | $454K | $256K-80.5% | $1.3M-77.2% | $5.7M+3.6% | $5.5M+730.2% | $668K+229.1% | $203K |
| Free Cash Flow | -$158.8M | -$144.1M-30.6% | -$110.3M-12.9% | -$97.7M-67.9% | -$58.2M-70.2% | -$34.2M-130.3% | -$14.8M |
| Investing Cash Flow | $166.4M | -$32.8M+82.2% | -$184.7M-279.5% | $102.9M+245.8% | -$70.6M+70.9% | -$242.2M-893.5% | -$24.4M |
| Financing Cash Flow | $20.9M | $196.1M-21.3% | $249.3M+368.8% | $53.2M-59.0% | $129.6M-30.4% | $186.4M+55.0% | $120.3M |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
EWTX Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 |
|---|---|---|---|---|---|---|
| Return on Equity | 0.0%0.0pp | 0.0%0.0pp | 0.0%+19.5pp | -19.5%-3.9pp | -15.6% | N/A |
| Return on Assets | 0.0%0.0pp | 0.0%0.0pp | 0.0%+18.4pp | -18.4%-3.4pp | -15.0%-2.0pp | -13.1% |
| Current Ratio | 19.85-0.1x | 19.93+0.4x | 19.50-2.0x | 21.53-5.4x | 26.97-2.9x | 29.86 |
| Debt-to-Equity | 0.060.0x | 0.060.0x | 0.070.0x | 0.060.0x | 0.04 | N/A |
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, FCF Margin.
Similar Companies
Where Edgewise Therapeutics, Inc. Ranks
Frequently Asked Questions
Is Edgewise Therapeutics, Inc. profitable?
No, Edgewise Therapeutics, Inc. (EWTX) reported a net income of -$168K in fiscal year 2025.
What is Edgewise Therapeutics, Inc.'s EBITDA?
Edgewise Therapeutics, Inc. (EWTX) had EBITDA of -$189.1M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Edgewise Therapeutics, Inc.'s return on equity (ROE)?
Edgewise Therapeutics, Inc. (EWTX) has a return on equity of 0.0% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Edgewise Therapeutics, Inc.'s free cash flow?
Edgewise Therapeutics, Inc. (EWTX) recorded an outflow of $144.1M in free cash flow during fiscal year 2025. This represents a -30.6% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Edgewise Therapeutics, Inc.'s operating cash flow?
Edgewise Therapeutics, Inc. (EWTX) recorded an outflow of $143.8M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Edgewise Therapeutics, Inc.'s total assets?
Edgewise Therapeutics, Inc. (EWTX) had $552.6M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Edgewise Therapeutics, Inc.'s capital expenditures?
Edgewise Therapeutics, Inc. (EWTX) invested $256K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Edgewise Therapeutics, Inc. spend on research and development?
Edgewise Therapeutics, Inc. (EWTX) invested $151.4M in research and development during fiscal year 2025.
What is Edgewise Therapeutics, Inc.'s current ratio?
Edgewise Therapeutics, Inc. (EWTX) had a current ratio of 19.85 as of fiscal year 2025, which is generally considered healthy.
What is Edgewise Therapeutics, Inc.'s debt-to-equity ratio?
Edgewise Therapeutics, Inc. (EWTX) had a debt-to-equity ratio of 0.06 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Edgewise Therapeutics, Inc.'s return on assets (ROA)?
Edgewise Therapeutics, Inc. (EWTX) had a return on assets of 0.0% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Edgewise Therapeutics, Inc.'s cash runway?
Based on fiscal year 2025 data, Edgewise Therapeutics, Inc. (EWTX) had $61.1M in cash against an annual operating cash burn of $143.8M. This gives an estimated cash runway of approximately 5 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Edgewise Therapeutics, Inc.'s Piotroski F-Score?
Edgewise Therapeutics, Inc. (EWTX) has a Piotroski F-Score of 0 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Edgewise Therapeutics, Inc.'s earnings high quality?
Edgewise Therapeutics, Inc. (EWTX) reported a net loss of $168K while operations used $143.8M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.